Related Experiment Video
Updated: Apr 24, 2026
An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
Published on: January 9, 2020
Application of an LC-MS/MS method to the pharmacokinetics of TM-2, a potential antitumour agent, in rats
Lei Men1, Yunli Zhao1, Hongli Lin1
1School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.
Abstract:
TM-2 is a novel semi-synthetic taxane derivative, selected for preclinical development based on its greater anticancer activity and lower toxicity compared with docetaxel. In this study, a rapid and sensitive analytical method based on ultra performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed for the determination of TM-2 in rat plasma. The biological samples were extracted with methyl tert-butyl ether and separated on a C18 column (50 mm × 2.1 mm, 1.7 µm) using a mobile phase consisting of acetonitrile and 2 mM ammonium acetate. The standard curves were linear over the range 5-1000 ng/mL in rat plasma. The precision (relative standard deviation, RSD, %) were within 14.5%, and the accuracy (relative error, RE, %) ranged from -1.56 to 2.36%. Recovery and matrix effect were satisfactory in rat plasma. The validated method was successfully applied to pharmacokinetic studies after intravenous administration of TM-2 to rats. The pharmacokinetics of TM-2 in rats were characterized by a large volume of distribution and a long half-life of elimination after single dose (4, 8, and 16 mg/kg), and a good correlation was observed between AUC and dose. The preclinical data will be useful for the design of subsequent trials of TM-2.
Insights
A new anticancer drug, TM-2, shows promise with higher efficacy and lower toxicity than docetaxel. A validated LC-MS/MS method quantifies TM-2 in rat plasma, supporting its preclinical development.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Preclinical Drug Development
Background:
- TM-2 is a novel semi-synthetic taxane derivative.
- It exhibits superior anticancer activity and reduced toxicity compared to docetaxel.
- Preclinical evaluation is essential for its further development.
Purpose of the Study:
- To develop and validate a sensitive analytical method for quantifying TM-2 in rat plasma.
- To apply the validated method in pharmacokinetic studies of TM-2.
- To characterize the pharmacokinetic profile of TM-2 in rats.
Main Methods:
- Ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed.
- Methyl tert-butyl ether was used for plasma sample extraction.
- A C18 column with acetonitrile and ammonium acetate mobile phase was utilized.
Main Results:
- The LC-MS/MS method demonstrated linearity from 5-1000 ng/mL.
- High accuracy (RE: -1.56 to 2.36%) and precision (RSD: ≤14.5%) were achieved.
- The method was successfully applied to determine TM-2 pharmacokinetics, revealing a large volume of distribution and long half-life.
Conclusions:
- A validated LC-MS/MS method enables accurate TM-2 quantification in rat plasma.
- TM-2 exhibits favorable pharmacokinetic properties in rats.
- These preclinical findings support the progression of TM-2 into further clinical trials.
More Related Videos
09:58Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
Published on: April 18, 2018
09:26Functional Magnetic Resonance Spectroscopy at 7 T in the Rat Barrel Cortex During Whisker Activation
Published on: February 8, 2019